3 research outputs found
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (Nâ=â94), MGUS (Nâ=â20) and multiple myeloma (MM, Nâ=â52) vs. healthy adults (Nâ=â30). MFC detected clonality in virtually all AL amyloidosis (99%) patients. Furthermore, we developed an automated risk-stratification system based on BMPCs features, with independent prognostic impact on progression-free and overall survival of AL amyloidosis patients (hazard ratio:ââ„â2.9;Pââ€â.03). Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUCâ=â0.74;Pâ<â.001), and might potentially be used as biomarkers for the identification of MGUS and MM patients, who are candidates for monitoring pre-symptomatic organ damage related to AL amyloidosis. Altogether, this study addressed the need for consensus on how to use flow cytometry in AL amyloidosis, and proposes a standardized MFC-based automated risk classification ready for implementation in clinical practice
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderateâsevere in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderateâsevere in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19